Teva’s generic Viread launches

Tevs has introduced its exclusive generic of Gilead’s Viread (tenofovir disoproxil fumarate), the company announced Friday. The drug is indicated to treat HIVE in adults and pediatric patients ages 2 years old and older, as well as chronic hepatitis B in patients ages 12 years old and older.

“Currently, 1.1 million people in the U.S are living with HIV and an estimated 850,000 to 2.2 million have chronic hepatitis B virus infection,” Teva executive vice president of North America commercial Brendan O’Grady said. “The launch of generic Viread is an important addition to our portfolio; but, more importantly, it brings an effective, affordable treatment option to these patients in an area that’s lacking.”

Teva’s generic will be available in 300-mg dosage strength tablets. The product had U.S. sales of roughly $762 million for the 12 months ended October 2017, according to IQVIA data.